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Abstract
Juvenile idiopathic arthritis (JIA) is the most common form of chronic synovial 
joint inflammation in children. It potentially leads to disability and psychosocial 
outcomes for children and their families. In the absence of appropriate treatment, 
this can lead to joint destruction and disability. Thus, early diagnosis and aggressive 
treatment are essential. With the presentation of new biologic DMARDs, based on 
understanding the disease pathophysiology and molecular pathogenesis, the course 
of the disease and its outcome have been changed profoundly. In this chapter, the 
early diagnosis, appropriate treatment, and outcomes approaches are described. 
These include the latest diagnosis and management options.
Keywords: juvenile idiopathic arthritis, children, chronic arthritis, oligoarthritis, 
polyarthritis, spondyloarthritis, psoriatic arthritis
1. Introduction
Juvenile rheumatoid arthritis (JRA) is the most common rheumatic childhood 
disease and one of childhood’s most common chronic diseases with unknown 
etiology and complex genetics. The new nomenclature applies the term juvenile 
idiopathic arthritis (JIA) [1].
Arthritis means intra-articular swelling or the presence of two signs or 
symptoms: limited range of motion, pain on motion, warmth, and redness. 
Intra-articular swelling may be due to intra-articular effusion or an increase in 
synovial thickness. In terms of the duration of arthritis, it can be divided into two 
categories: 1. Acute: for less than six weeks, 2. Chronic: more than six weeks [2]. In 
terms of the location of joint involvement, it can be divided into three categories: 1. 
Peripheral arthritis: means joints involvement of upper and lower limbs, 2. Axial: 
includes spinal joints involvement, and 3. Referral: includes the involvement of 
the hip joint [3]. In terms of the number of joints involved in a disease, arthritis 
can be divided into three categories: 1. Monoarthritis: means single joint involve-
ment, 2. Oligoarthritis: means simultaneous involvement of four joints or less, and 
3. Polyarthritis: it means the simultaneous involvement of more than four joints. 
In terms of the pattern and timing of arthritis spread, it can be divided into three 
categories: 1. Migratory: it means the rotation of the involved joints in a short period 
of several hours to a few days, which means that the affected joint improves and 
the other joint becomes involved. 2. Additive: this means that another joint or joints 
are added to the joint involved. 3. Intermittent: involvement occurs occasionally, 
and at intervals, the patient has no joint symptoms (such as Lyme disease or FMF 
[4]. In terms of the distribution of involved joints, arthritis can be symmetric or 
asymmetric. Symmetric arthritis refers to the involvement of the same joint on the 
opposite side, such as Rheumatoid arthritis, Systemic lupus erythematosus, and RF 
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positive polyarticular JIA. Asymmetric arthritis is characterized by the involvement 
of different joints in two sides of the body. This occurs in many childhood arthritis 
cases such as reactive arthritis, psoriatic arthritis, and Lyme disease. Arthritis can 
be inflammatory or non-inflammatory. In the case of inflammatory, inflammation 
of articular structures such as synovium, synovial cavity, and entheses occur. Non-
inflammatory arthritis is an articular disease caused by mechanical or structural 
changes in the joint. These joint diseases can be due to cartilage or meniscus injuries 
with or without accompanying changes in the subchondral bone or maybe changing 
in joint anatomy due to congenital, developmental, metabolic, or previous inflam-
matory diseases [3, 4].
Regarding juvenile idiopathic arthritis, according to the previous definitions, we 
are faced with chronic arthritis with a period of at least six weeks in the age group 
under 16 years without an unknown etiology.
2. Epidemiology and immunopathogenesis
Since different criteria and classifications (including previous definitions of 
JRA, JCA, and JIA) have been presented for this disease over the decades, conduct-
ing various epidemiological studies to determine the exact incidence and prevalence 
of the disease has faced severe challenges. The disease appears to be less common 
in African-American and Asian populations in the United States [5]. The disease 
has an average prevalence of about one per thousand children under the age of 16, 
similar to acute lymphoblastic leukemia and type 1 diabetes in children [6]. In most 
countries, the ratio of females to males is about two to one or three to one. However, 
these ratios vary depending on the age of onset and the type of disease. The peak of 
the disease is between two and four years old, although it varies depending on the 
sex and type of disease [7].
The pathogenesis and etiology of the disease are unknown. Like many autoim-
mune diseases, interactions between genetic factors, immune mechanisms, and 
environmental factors are involved in developing the disease. Patterns consistent 
with Mendelian or Monogenic inheritance have not been observed in this disease. 
In many cases, the level of risk to other family members has only slightly increased. 
HLA types are probably associated with the disease and its subtypes. Patients 
with early-onset oligoarticular JIA who have a relatively high concordance among 
siblings are most likely to have isolated associations with these subgroups. Some 
genes involved in JIA may be a risk factor for the disease but are sometimes neutral 
or even protective [8].
The primary clinical manifestation of JIA is chronic joint swelling that may lead 
to deformity of the affected joints due to stretching of the tendons and ligaments 
around the joint. Enzymes released from inflammatory cells inside the synovium or 
joint fluid may damage the collagen and proteoglycan matrix in the joint. Osteoclasts 
activation results from cytokine production by cells in inflammatory tissue, and the 
final pathway is probably bone demineralization and bone destruction [9].
One of the pathological hallmarks of JIA is a tumor-like spread of inflamed 
synovial tissue, which is called pannus, leading to further joint destruction. Pannus 
consists of the synoviocyte proliferation and the invasion of synovial tissue by 
inflammatory cells (including lymphocytes, macrophages, and dendritic cells). The 
infiltration of these cells into the synovium is due to vascular factors, cytokines, 
adhesive molecules, and chemokines. Various inflammatory cells have been found 
in synovial fluid. As the disease progresses, the pannus expands into the synovial 






Due to the heterogeneity of JIA disease, its classification remains a challenge. 
Classification criteria have been developed for research purposes and should not be 
used as diagnostic criteria at a patient’s bedside. However, treatment and prognosis 
options may still help establish a common language and understanding of disease 
forms. International League of Associations of Rheumatology (ILAR) recognizes 
that this disease is an exclusive diagnosis. The characteristics of the disease and its 
etiology are the uncertainty of the disease onset before the age of 16 and its duration 
for at least six weeks.
According to ILAR classification, JIA is divided into seven subgroups 
(Table 1).
ILAR criteria are considered as standard, and still, the proposed new systems 
need further approval. With a greater understanding of the genetics and pathobiol-
ogy of arthritis, it is hoped that future classifications will suggest more homoge-
neous JIA groups with biologically distinct diseases [2].
3.1 Systemic JIA
Systemic arthritis is considered a young adult still’s disease. Arthritis is present 
in one or more joints with fever for at least two weeks. The disease most commonly 
presents with daily fevers, at least three days (quotidian spiking fevers). In addi-
tion, the child should have at least one of the following symptoms: evanescent 
erythematous rash, hepatomegaly or splenomegaly, generalized lymphadenopathy, 
or serositis.
Systemic juvenile idiopathic arthritis (SJIA) is an autoinflammatory disease dif-
ferent from other forms of childhood arthritis and requires different treatments. In 
this disease, the child has symptoms of systemic involvement, which is less common 
in other forms of JIA. No autoantibodies are found in the serum of patients, and the 
primary disorder is in the inherited immune deficiencies system [2].
3.2 Polyarthritis: rheumatoid factor (RF) positive or negative
In addition to the involvement of at least five joints, patients with positive rheu-
matoid factor (RF) type should have at least two RF-IgM-positive results at least 
Systemic arthritis
Polyarthritis: rheumatoid factor negative







a. Fits no other category
b. Fits more than one category
Table 1. 
Classification criteria for juvenile idiopathic arthritis: 2001.
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three months apart, although this test is often performed only once at the begin-
ning of the diagnosis. Children with first-degree relatives with psoriasis, systemic 
arthritis, or manifestations of enthesitis-related arthritis are excluded from this 
category [10].
3.3 Oligoarthritis, persistent or extended
The disease involves a subset of patients previously classified as pauciarticular 
JRA. The disease is divided into two subgroups:
Persistent arthritis - refers to cases in which a child has one to four joints involved 
during the first six months of illness, but the number of joints involved never 
reaches five or more during the disease.
Extended arthritis- refers to children whose number of affected joints extends to 
five or more after the first six months of disease.
RF positive, first-degree relatives with psoriasis and concomitant or systemic 
manifestations are excluded from this classification [10].
3.4 Enthesitis-related arthritis (ERA)
This group of diseases refers to cases where enthesitis-related arthritis co-exist 
or enthesitis alone accompanies two or more of the following:
• Sacroiliac joint tenderness, or inflammatory lumbosacral pain
• Human Leukocyte Antigen B27 (HLA-B27) positive
• First-degree relatives with acute anterior uveitis, ankylosing spondylitis, 
inflammatory bowel disease, or reactive arthritis
• Acute anterior uveitis
• Arthritis onset in a boy over six years old
Children with first-degree relatives with psoriasis, RF positive, or systemic 
arthritis are excluded from this group.
This group includes some children formerly known as spondyloarthropathies. 
Also, some children may develop psoriatic arthritis in the future but do not cur-
rently fulfill its diagnostic criteria [10].
3.5 Psoriatic arthritis
Psoriatic arthritis is defined as children who have psoriasis and arthritis together 
or children with arthritis who have two of the following three:
1. Psoriasis in first-degree relatives
2. Dactylitis
3. Nail disorders, including pitting or onycholysis
Children with manifestations of arthritis associated with enthesitis or systemic, 





If patients do not meet the criteria mentioned in one of the above subgroups or 
have rejection manifestations, they fall into this subgroup. Also, if children meet the 
criteria of more than one group, they will be included in this group [10].
4. Diagnosis
The diagnosis of JIA is based on the history and findings of the physical exami-
nation and the exclusion of all other possible causes. Further evaluation, such as 
plain x-ray, ultrasound, nuclear bone scan, or MRI, is recommended when a physi-
cal examination does not prove definite arthritis.
5. Laboratory examination
Laboratory tests that may be performed to rule out other causes of arthritis or to 
determine the type or activity of the disease include the following [11]:
• Inflammatory markers: level of erythrocyte sedimentation rate (ESR) and 
C-reactive protein (CRP) level
• Complete blood cell count (CBC) and metabolic panel, including serum uric 
acid and serum lactate dehydrogenase (LDH)
• Liver function tests and evaluation of renal function with serum creati-
nine levels
• Anti-nuclear antibody test (ANA)
• Rheumatoid factor (RF) and Anti-cyclic citrullinated peptide (Anti-CCP)
• Additional tests: Serum total protein, Serum albumin, Fibrinogen, Ferritin, 
D-dimer, Angiotensin-converting enzyme (ACE), Anti-streptolysin O (ASO), 
Anti-DNase B, and urinalysis
• Tests to check for infectious causes, as the case may be.
6. Imaging studies
Radiographic changes in JIA include [11]:
• Swelling of soft tissue
• Osteopenia or Osteoporosis







• Epiphyseal compression fracture
• Joint subluxation
• Synovial cysts
These changes are usually seen in children about one to two years after the onset 
of the disease and if not treated properly.
7. General principles of treatment
The medical treatment includes pharmacological and non-pharmacological 
treatments performed by a multi-group team. The following are considered in the 
group of non-drug therapies [11];
• Psychosocial interventions




8. Disease course, outcome, and prognosis
JIA is a nomenclature that includes different diseases with different patho-
physiology, manifestations, course, and outcome. With early diagnosis and 
aggressive appropriate step-wise treatment, the long-term outcome of JIA has 
improved in the last forth decades. There are different criteria for determining 
disease outcomes. Wallace et al. defined a set of criteria for the evaluation of 
clinical outcomes in JIA. Inactive disease (according to Wallace) criteria was 
defined as a state of no active joints, no systemic symptoms, no uveitis, normal 
erythrocyte sedimentation rate (ESR), and/or C-reactive protein (CRP), and a 
physician’s global assessment of disease activity indicating no disease activity. 
Furthermore, there are some different definitions for disease remission. The 
American College of Rheumatology criteria for complete remission of the disease 
are as follows [12]:
• Lack of inflammatory joint pain
• Lack of morning stiffness
• Lack of fatigue




• Lack of damage progression, which is determined by consecutive radiographic 
examinations
• Lack of high ESR and CRP levels
Also, different risk factors and prognostic factors exist for each of the subtypes. 
It potentially can cause serious complications, such as musculoskeletal deformities 
(including joint deformity and contracture), short stature, leg-length discrepancy, 
osteopenia and osteoporosis, increased risk of infections, cataract, decreased visual 
acuity, synechia, blindness, and macrophage activation syndrome. Each subtype’s 
expected course, poor prognostic factors, and outcomes will be discussed later 
in detail.
9. Systemic-onset JIA
9.1 Clinical manifestations and diagnosis
Systemic JIA was formerly known as pediatric still’s disease, systemic JRA, or 
systemic-onset juvenile idiopathic arthritis. This type of JIA is characterized by 
intermittent spiky fevers, evanescent erythematous rash, and arthritis. This disease 
is more similar to autoinflammatory diseases and may be different from other types 
of JIA. Diagnosis can be challenging because there are no specific diagnostic tests, 
and arthritis, which is essential for a definitive diagnosis, is often absent early in the 
disease. In addition, infections, malignancies, and other diagnoses should be ruled 
out before being labeled as these diseases can similarly cause fever, skin rashes, and 
joint pain. The diagnosis is clinical and is based on quotidian pattern (daily fevers 
spikes), typical evanescent erythematous rashes, and arthritis is characterized by 
typical laboratory findings, including leukocytosis with neutrophil predominance, 
elevated acute phase reactants including thrombocytosis, and high ferritin. In gen-
eral, unfortunately, the disease does not have a specific diagnostic test. Differential 
diagnoses include infectious arthritis, other autoimmune and inflammatory 
disorders, malignancy, and malaria [13].
9.2 Treatment
In children with mild to moderate symptoms and without debilitating symp-
toms, a non-steroidal anti-inflammatory drug other than aspirin is recommended 
as initial treatment. In general, a drug test with non-steroidal anti-inflammatory 
drugs (NSAIDs) alone should not take more than a few weeks. The addition of 
adjuvant medication is common in children who find or continue to have significant 
symptoms despite treatment.
Traditionally, many pediatric rheumatologists add a glucocorticoid to the patient 
who has not responded to initial NSAIDs treatment or who has had a severe disease 
from the beginning. However, long-term use of glucocorticoids is associated with signif-
icant side effects. Biological agents, especially interleukin 1 and 6 blockers, are used as 
a primary and single treatment with increasing frequency. These factors are effective in 
reducing clinical symptoms in patients resistant to NSAIDs and glucocorticoids. There 
are growing findings that suggest that biological agents may also be helpful in the care 
of children with severe illness instead of glucocorticoids at the time of diagnosis. The 
decision to start treatment with a biological agent alone or combined with glucocorti-
coids is initially made considering the type of biological agent used, and after discussing 
the potential benefits and harms of treatment for the patient and family.
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In patients who do not respond to the initial test of treatment with an NSAID 
alone, or in those whose early symptoms include high fever, other severe systemic 
symptoms, or debilitating polyarthritis, it is recommended that a biological agent 
such as Anakinra, Canakinumab, or Tocilizumab is added until a glucocorticoid is 
taken. Anakinra is used in some at a dose of 2 mg per kilogram of body weight daily 
up to a maximum of 100 mg. Canakinumab is usually given at a monthly dose of 
4 mg per kilogram of child body weight with a maximum dose of 300 mg. Typically, 
12 mg per kg intravenous injection or 162 mg subcutaneous injection is used every 
two weeks for children weighing less than 30 kg. Also, 8 mg per kg intravenous 
injection with a maximum dose of 800 mg every two weeks or 162 mg subcutaneous 
injection every week for higher body weights.
It is recommended that glucocorticoids be used when they do not respond 
immediately to a biological agent. When the current definition of an immediate 
response varies from center to center, some pediatric rheumatologists wait more 
than a week to add a glucocorticoid if polyarthritis, fever, and rash persist. They all 
add a glucocorticoid if there is evidence of severe macrophage activation syndrome 
or serositis. Both glucocorticoids and biological agents usually persist until disease 
control. Clinicians may then discontinue glucocorticoids first because the drug is 
associated with unavoidable intoxication in long-term use. Discontinuation of the 
biological agent may be possible if the disease is controlled. Prednisolone should 
be limited to o.5–1 mg/kg, although doses higher than 2 mg/kg or pulsed treatment 
with methylprednisolone may be necessary in severe cases. The treatment in cases 
with the polycyclic course and recurrent attacks is similar to the initial treatment. 
Treatment of the chronic and persistent disease depends on whether the patient 
has early systemic signs and symptoms (including fever, rash, and serositis), early 
arthritis, which can be progressive and destructive, or both. Interleukin 1 and 6 
blockers are the most effective biological agents for early systemic disease and may 
also be effective for chronic arthritis. Tumor necrosis factor (TNF) alpha-blockers, 
concomitant T-cell stimulation blockers (Abatacept), and methotrexate can be 
used as adjunctive therapies to treat chronic arthritis. Other non-biological disease-
modifying anti-rheumatic drugs (DMARDs) such as cyclosporine and tacrolimus, 
and cytotoxic agents such as cyclophosphamide are complementary choices in cases 
that do not respond to standard treatment containing biological agents.
The potential toxicity of drugs used in systemic arthritis should be carefully 
evaluated compared to the progressive, debilitating side effects and often the persis-
tence of uncontrolled disease. Therefore, patients presenting with severe manifesta-
tions of the disease or those who resist treatment with NSAIDs should be referred 
to an experienced pediatric rheumatologist for disease management. Screening and 
monitoring of the disease are essential in the patients being treated [14, 15].
9.3 Course, prognosis, and complications
The course of systemic JIA is highly variable, although there are three typi-
cal pre-biological patterns in the disease: monophasic, polycyclic, and persistent 
(chronic). In the monophasic pattern, complete remission usually occurs within 4 
to 6 months (occasionally in two to four years) and does not recur. In polycyclic or 
relapsing form, flares of systemic manifestations are with mild arthritis, and among 
them, remission and inactivity of the disease occur. This period can vary from a 
few months to several years. Finally, persistent destructive arthritis is often present 
in the persistent type despite reducing systemic manifestations, usually the most 
common form of the disease (50%) [16].





1. Systemic manifestations without or with mild arthritis, including fever, skin 
rashes, and sometimes recurrent macrophage activation syndrome.
2. Persistent (chronic) systemic manifestations and progressive arthritis.
3. Progressive destructive arthritis despite improvement of systemic manifes-
tations. Despite treatment, some patients develop progressive destructive 
arthritis.
Systemic JIA-induced morbidity and mortality have decreased with treatment 
progress, but mortality is still high in patients with severe disease, especially those 
with recurrent or unknown macrophage activation syndrome and severe pulmo-
nary or vascular complications [17]. Patients with active disease (those with fever, 
arthritis, high platelet count, persistent need for glucocorticoids) six months 
after disease onset have a worse prognosis for disease persistence and destructive 
arthritis [18].
Macrophage activation syndrome is the most common complication of systemic 
JIA. With the early detection and application of biologic DMARDs such as IL1 and 
IL6 inhibitors, complications such as severe growth retardation and osteoporosis 
are currently less common. There may be an increased incidence of rare but severe 
pulmonary complications that require further investigation.
9.4 Macrophage activation syndrome
Macrophage activation syndrome (MAS) is a potentially life-threatening com-
plication of systemic JIA that should be treated as a life-threatening emergency. 
Clinical and histopathological features of macrophage activation syndrome are 
similar to hereditary lymphohistiocytic hemophagocytosis or HLH. However, diag-
nostic criteria for it are often not used to diagnose MAS in systemic JIA. Evidence 
suggests that there is a common genetic component in patients with systemic 
arthritis and MAS, as well as protein-altering variants in genes associated with 
HLH [19].
9.4.1 Clinical manifestations
Typically, MAS occurs during the first few days or weeks after the systemic-
onset JIA, although it can occur at any time during the disease course. MAS occurs 
in 10% of children with systemic JIA but can develop subclinically in about 30–40% 
of other patients. Some patients have recurrent attacks of MAS. Triggers for this 
syndrome may be viral or bacterial infections or the administration of new drugs, 
but the initial irritating incident is often not apparent [20].
Children may present with spontaneous bleeding, bruising, liver dysfunction, 
drowsiness, seizures, coma, or shock. Persistent fever and skin rash (as opposed 
to intermittent daily fever and the typical evanescent skin rash of mild acute 
systemic JIA), lymphadenopathy, and hepatosplenomegaly are other common 
findings. White blood cell count, hemoglobin, platelet count, and serum fibrinogen 
typically decline abruptly. Liver function tests, triglycerides, and LDH increase 
rapidly. Ferritin can also reach as high as 10,000 ng/ml or even higher. In addition, 
a paradoxical decrease in erythrocyte sedimentation rate (ESR) due to fibrinogen 
consumption occurs, which is a vital diagnostic key. Typically, a bone marrow 
aspiration reveals multiple benign macrophages that indicate hemophagocytosis. 
However, not all bone marrow samples from patients with MAS show such a finding 




Early diagnosis of MAS in a patient with systemic JIA may be difficult because 
systemic JIA flare-ups have similar clinical manifestations. In addition, a review of 
published literature suggests that patients treated with biologics may have fewer 
clinical manifestations of MAS, which may make it even more difficult to diagnose; 
for example, tocilizumab-treated patients have no fever or lower level of fever, and 
their CRP and ferritin levels are significantly lower. Diagnostic criteria for HLH are 
often not applicable to MAS in patients with systemic arthritis. Although these syn-
dromes are clinically similar, HLH criteria are so strict that they cannot detect early 
MAS in patients with systemic JIA when they respond more to treatment. Part of the 
problem lies in the fact that patients with systemic JIA naturally have significantly 
increased levels of white blood cells and platelets along with acute-phase reactants 
such as ESR and fibrinogen so that normal premature levels of these blood tests can 
be misleading because they are caused by declining levels and is a signal of imminent 
MAS. For this reason, many efforts are underway to develop applicable clinical diag-
nostic criteria and scoring tools to diagnose MAS in patients with systemic JIA [21].
The 2016 classification criteria for MAS in systemic arthritis were expanded to 
identify more valuable criteria by combining consensus methods by experienced 
individuals and analyzing actual patients’ data.
These criteria require increased ferritin and one of the other two criteria. These 
criteria include [22]:
• Thrombocytopenia (platelets 181,000 or less)
• Elevated liver enzymes (including AST > 48 U / L)
• Hypertriglyceridemia (above 156 mg /dl)
• Hypofibrinogenemia (360 mg/dl or less)
A diagnostic scoring tool to differentiate MAS in systemic arthritis from active 
systemic JIA without MAS, called systemic MAS scoring MAS / sJIA (MS), was devel-
oped and validated in 2019. In this criterion, multinational patient data collected were 
used to classify the MAS in 2016. Fever is a mandatory criterion for diagnosis and does 
not fit into scoring, although, as noted above, it may not be present in patients with 
systemic JIA treated with tocilizumab even in the presence of MAS. This scoring still 
needs validation in the clinical field and may need to be revised to include biological 
use in its calculations. This tool can also differentiate between these two diseases with 
high sensitivity and specificity. The MAS / HLH (MH) score strongly confirms the 
age of onset, neutrophil count, fibrinogen, splenomegaly, platelet count, and hemo-
globin. Having an age of 16 years or less at the onset of the disease and neutrophil of 
less than or equal to 1400 per liter are the most critical factors in differentiating HLH 
from macrophage activation syndrome involving systemic JIA [23].
9.4.3 Treatment
When MAS is diagnosed or suspected, treatment should be started urgently 
with high-dose glucocorticoids, often using a 30 mg/ml methylprednisolone pulse 
at a maximum dose of 1 gr daily intravenously. There have been case reports of 
successful treatment with cyclosporine, cyclophosphamide, etoposide, or anakinra. 
Treatment of resistant MAS cases in patients with systemic JIA is the same as treat-





10.1 Clinical manifestations and diagnosis
Children with JIA of the oligoarticular type, formerly known as juvenile rheu-
matoid arthritis (JRA) of pauciarticular JRA type, have involvement of four joints 
or less during the first six months after the disease onset. These patients are divided 
into two main subgroups: 1. Patients who do not have more joint involvement after 
the first six months of the disease have persistent oligoarticular JIA. 2. Those with 
four or fewer joints are involved during the first six months of disease onset, but 
more joints are added over time, resulting in five or more joints eventually becom-
ing involved, known as extended oligoarticular JIA [2].
Oligoarticular JIA is the most common group of JIA, accounting for almost half 
of all cases. In the USA and Europe, the disease is more common in girls than boys 
and peaks at two to three years of age. The typical manifestation of the disease is 
painless limping. Large joints, especially the knees and ankles, are the most com-
monly involved joints, but the pelvic joints are never the primary joints involved. 
Except for uveitis, there are no obvious systemic manifestations [25].
Diagnosis of oligoarticular JIA in children is made with arthritis of four joints 
or less during the first six months of the disease by excluding the other causes of 
oligoarthritis. There are no diagnostic laboratory tests for the disease. Antinuclear 
antibodies (ANA) are frequently present in these patients and are associated with 
an increased risk of iridocyclitis. Patients with an elevated ESR or unexplained 
anemia are more likely to have a recurrent disease and become an extended 
oligoarticular JIA. Differential diagnoses of oligoarticular JIA include the other 
types of JIA such as psoriatic arthritis, polyarticular JIA and ERA, Lyme disease, 
IBD, pigmented villonodular synovitis, other infectious, autoinflammatory, and 
autoimmune diseases, and malignancy, all of which may involve four or fewer 
joints at the onset [26, 27].
Recurrence occurs in approximately a quarter of initially healthy patients. Some 
patients with the oligoarticular disease eventually develop chronic degenerative 
arthritis. Manifestations in the first six months of the disease poor prognostic 
factors include symmetric involvement, ankle or wrist involvement, laboratory 
evidence of inflammation (elevation of ERS or CRP), radiographic evidence of joint 
destruction, and hip or cervical joints arthritis [28].
10.2 Treatment
Patients with mild to moderate disease activity, lack of risk factors for poor 
prognosis, and lack of joint stiffness usually respond to non-steroidal anti-inflam-
matory drugs and intra-articular injections of glucocorticoids. However, patients 
with more significant illnesses who do not respond to initial treatment for intra-
articular injection or who initially have severe disease activity and poor prognostic 
risk factors require treatment with methotrexate or other DMARDs. Biological 
agents such as TNF blockers are used in patients with a moderate or severe dis-
ease with poor prognostic manifestations who do not respond to treatment with 
non-biological DMARDs. TNF blockers are also used in patients with progressive 
oligoarticular JIA and patients with uveitis [28–31].
10.3 Course, prognosis, and complications
Uveitis is the worst complication of the disease, occurring in approximately a 
quarter of patients with oligoarticular JIA. Patients with detectable ANA and those 
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under the age of six at the time of diagnosis are at the highest risk. Mainly, there 
are no symptoms of uveitis, so routine screening is essential. An ophthalmologist 
should perform screening and a thorough examination with a slit lamp, and an 
alternative optometric or fundoscopic examination is insufficient. Complications 
include cataracts, synechia, glaucoma, band keratopathy, and macular edema 
(Table 2) [32].
The leg-length discrepancy is the second most common complication of oligo-
articular JIA. This complication frequently occurs in both bone length and width. 
Injection of glucocorticoids into the knee and ankle joint early in the course of the 
disease may prevent this complication [33].
Referral
• Patients should be referred at the time of diagnosis, or suspicion, of JIA
Initial screening examination
• Should occur as soon as possible and no later than six weeks from referral
• Symptomatic patients should be seen within a week of referral
Ongoing screening
• Screening at two-monthly intervals from the onset of arthritis for six months
• Followed by 3–4 monthly screening for time outlined below:
 ○ Oligoarticular JIA, psoriatic arthritis, and enthesitis-related arthritis irrespective of ANA status onset 
under 11 years





 ○ Polyarticular, ANA positive JIA, onset <10 years
Age at onset Length of screening
<6 years 5 years
6–9 years 2 years
 ○ Polyarticular, ANA negative JIA, onset<7 years
Five-year screening for all children
 ○ Systemic JIA and rheumatoid factor positive polyarticular JIA
Uveitis risk is very low; however, diagnostic uncertainty in the early stages and overlap of symptoms may 
mean initial screening is indicated
 ○ All categories, onset >11 years
One year screening for all children
 ○ After stopping immunosuppression, e.g., methotrexate
Two-monthly screening for six months, then revert to previous screening frequency as above
 ○ After discharge from screening
Patients should receive advice about regular self-monitoring by checking vision uniocularly once weekly 
and when to seek medical advice
Screening may need to continue indefinitely in situations where a young person may be unable to detect a 
change in vision or be unwilling to seek re-referral
Annual check by an optometrist as a useful adjunct
Table 2. 







The age of onset of polyarticular JIA onset has a bi-modal distribution. The first 
peak is between the ages of two and five, and the second peak is between ten and 
14 years old. It is more common in girls than in boys of all ages [2].
The clinical presentation of polyarticular JIA varies and tends to show different 
patterns depending on the age of the disease onset. In children under ten years of 
age, polyarticular JIA often begins similar to oligoarticular disease with the involve-
ment of one or two joints. The progression of the disease is often subtle until an 
intercurrent infection dramatically exacerbates the symptoms of the disease. The 
disease inevitably progresses and spreads to five or more joints during the first six 
months of disease onset. Joint involvement is typically symmetrical. Older children 
and adolescents usually have a rapid onset of multi-joint involvement, including 
a large number of small joints of hands and feet within two to three months of the 
disease onset [34].
There are no diagnostic laboratory findings for JIA. However, patients may have 
an ANA-positive test and an increased ESR of 40 mm in the first hour or so, anemia, 
and hypergammaglobulinemia. In most patients, the Rheumatoid factor is negative. 
In some patients in this group, rheumatoid factor (RF) or anti-cyclic citrullinated 
peptide (Anti-CCP) is positive, which is associated with the severity of the disease, 
symmetrical involvement of small or medium-sized joints, degenerative course of 
arthritis, and prolongation of the disease with a rheumatoid arthritis-like course. 
Other autoantibodies are not commonly seen in patients with polyarticular JIA [35].
11.2 Diagnosis
Diagnosis is made in children with arthritis in more than four joints during the 
first six months of the disease and by rejecting other causes of polyarthritis.
11.3 Differential diagnoses
include several diseases that may be self-limiting or chronic, including other 
forms of JIA such as psoriatic, systemic, enthesitis-related, reactive arthritis, early-
onset rheumatoid arthritis, systemic lupus erythematosus, systemic vasculitis, 
sarcoidosis, inflammatory bowel disease, epiphyseal dysplasia, and minocycline-
induced autoimmunity [27].
11.4 Treatment and prognosis
Polyarticular JIA treatment aims to treat underlying synovitis and inflam-
mation. Immediate treatment that relieves the patient’s arthritic symptoms and 
protects the patient’s function is essential for a better outcome. The treatment 
regimens chosen depend on prognostic factors, disease activity, as well as physi-
cian and family preferences, which are adjusted based on the clinical response. 
Risk factors include positive RF, positive anti-CCP, and joint degeneration. Disease 
activity is measured by the clinical Juvenile Disease Activity Score based on ten 
joints (cJADAS-10). It is recommended that initial treatment with a DMARD be 
performed in all patients with polyarticular JIA. Methotrexate is preferable to 
sulfasalazine, leflunomide, or a three-drug combination of methotrexate, sul-
fasalazine, and hydroxychloroquine. Methotrexate at a dose of 10 mg per square 
meter of the body per week in patients with low disease activity or an anti-TNF 
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biological agent with methotrexate in cases with moderate to severe disease activ-
ity is primarily used. Indications for using a TNF blocker with or in comparison 
with methotrexate include the presence of severe polyarthritis, inferior prognostic 
manifestations, or factors associated with a poor response to methotrexate, such 
as predominant involvement of the axial joints. The NSAIDs are not suitable as 
a single drug but as adjunctive therapy to relieve symptoms. Folic acid or folinic 
acid supplements are used in all children with JIA receiving methotrexate, which 
has been shown to have beneficial effects, and there is no convincing conflicting 
data against them. In patients who do not respond to treatment with methotrexate 
and a TNF blocker, treatment decisions are made on a case-by-case basis. The use 
of abatacept or tocilizumab is preferable to switching the TNF blocker. Choices 
include using a combination of DMARDs, other biological agents, or a small 
molecule inhibitor under the supervision of an experienced pediatric rheumatolo-
gist. Adolescents with positive RF and positive Anti-CCP are likely to show early 
onset of rheumatoid arthritis. For this reason, these children should be treated like 
adults with moderate to severe rheumatoid arthritis [36].
12. Psoriatic JIA
12.1 Pathogenesis, clinical manifestations, and diagnosis
Psoriatic JIA or psoriatic arthritis is clinically non-homogenous. In children, 
the age of onset of the disease is bimodal. The first peak occurs mainly in preschool 
girls and has a clinical picture similar to oligoarticular JIA with a high probability 
of positive ANA. The second peak is in mid-to-late childhood and resembles 
adult-onset psoriatic arthritis. The presentation and severity of the disease can be 
quite different, and the skin manifestations of psoriasis can occur long after the 
onset of arthritis. Articular involvement may vary from mild enthesitis to poly-
articular involvement of the peripheral and axial joints. Inflammation may occur 
in only one joint or a large number of joints, with or without the involvement of 
the sacroiliac joints, spine, or peripheral entheses. Dactylitis or sausage-shaped 
swelling of the fingers is a common manifestation in younger children, while axial 
enthesitis-related arthritis is more common in older children. Enthesitis refers to 
inflammation of the joints where ligaments, tendons, capsules, fascia, and other 
fibrous structures attach to bone. Overt psoriasis Vulgaris may not be present. Nail 
pitting is more common in psoriatic JIA than skin-limited psoriasis. RF is typically 
negative and is considered an exclusion criterion. Inflammatory markers include 
ESR and CRP, and platelet counts may be mild to moderate but are often normal, 
even in the presence of polyarticular disease. Bone changes and joint space narrow-
ing indicate significant cartilage loss, typically seen only after the advanced disease 
onset [37].
Psoriatic arthritis is currently diagnosed in children where arthritis occurs in 
the presence of established psoriasis. However, classic skin rash during presenta-
tion does not occur in about half of children with psoriatic arthritis and sometimes 
occurs even ten years or more after the onset of the joint symptoms. Besides, 
psoriasis in young children may be mild, atypical, and transient, often mistaken for 
eczema initially; therefore, diagnostic uncertainty is expected. Laboratory tests and 
radiologic studies have limited value in diagnosing psoriatic arthritis [37].
Differential diagnoses of psoriatic arthritis mainly include other subtypes of 
JIA, particularly oligoarticular and RF negative polyarticular and enthesitis-related 





12.2 Treatment, prognosis, and outcome
Psoriatic arthritis is a relatively common subtype in JIA, but its clinical pre-
sentation can be very varied. Except for confirmation of suspected sacroiliitis by 
contrast-enhanced MRI, laboratory tests and radiological studies have limited 
value in managing psoriatic arthritis. Like other types of JIA, initial treatment for 
psoriatic arthritis depends on summing up all the clinical, laboratory, and radio-
graphic manifestations of the disease to prevent cartilage or bone damage. The 
standard treatment algorithm for psoriatic arthritis is similar to other JIA cases, 
with a few exceptions. Some rheumatologists use NSAIDs as the primary treatment 
for monotherapy. However, NSAIDs do not typically induce remission; therefore, 
it is generally best used with a DMARD in patients with extensive or moderate to 
severe disease. Arthritis in the large joints, as well as dactylitis of the fingers, may 
be treated with glucocorticoid injections. DMARDs are indicated at diagnosis in 
patients with multiple joint involvements or those who have not remission with 
intra-articular injection of glucocorticoids. Failure to achieve disease remission 
is followed by the addition of a secondary DMARD, or more commonly by anti-
TNF treatment. Systemic glucocorticoids are generally less commonly used, and 
antimalarial agents are avoided because of the risk of worsening psoriatic rash. The 
effectiveness of other biologic agents such as anti-IL-12/23, anti-IL-17, abatacept, 
apremilast, and Jak inhibitors has been shown in various studies [38].
Axial involvement in psoriatic arthritis is phenotypically similar to ankylos-
ing spondylitis. Treatment should be started in patients with psoriatic arthritis 
who have symptoms of axial involvement or limited spinal mobility, even if these 
changes have not yet been shown on plain graphs. Anti-TNF agents are generally 
most effective, while NSAIDs can relieve symptoms in a group of patients. Other 
DMARDs have minimal impact. Interleukin-17 blocking agents, such as Janus 
kinase (JAK) inhibitor, appear to be allowed in adult studies. Monitoring and treat-
ment of uveitis in psoriatic arthritis is similar to other subgroups [38].
Traditional treatment of psoriasis is indicated for skin disease associated with 
psoriatic arthritis. Usually, skin involvements are not very troublesome because 
joint manifestations occur early. After all, early use of systemic agents such as 
methotrexate and TNF inhibitors also has high effects on skin disease [39].
Poor outcomes and long-term disability are generally seen in patients who have a 
long delay in diagnosis or those who have not started effective treatment, although 
physicians or families often try to take necessary steps to induce disease remission [40].
13. Spondyloarthritis
13.1 Clinical manifestations and diagnosis
The terms spondyloarthropathy and spondyloarthritis refer to seronegative and 
related inflammatory diseases characterized by involvement of the spine (sacroiliitis 
and spondylitis), large joints (asymmetric oligoarthritis, especially of the lower 
extremities), and the entheses (enthesitis and enthesopathy). Diseases that fall into 
this category in children include enthesitis-related arthritis (undifferentiated spondy-
loarthritis), juvenile ankylosing spondylitis (differentiated spondyloarthritis), reac-
tive arthritis, psoriatic arthritis, and arthritis with inflammatory bowel disease [41].
The onset of the disease is gradual but may initially be followed by a febrile 
illness or a musculoskeletal trauma. Arthritis is usually oligoarticular, asymmetric, 
and initially involves the large joints of the lower extremity. The knee, ankle, and 
mid-foot are the most common joints involved during the presentation. Common 
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manifestations accompanied include painful ligaments or tendons at the junction 
with the bone (enthesitis), inflammatory back pain or sacroiliac pain, morning 
stiffness, and limited spine movement [41].
Extra-articular manifestations include anterior uveitis, related skin manifesta-
tions, and recurrent gastrointestinal complaints. These manifestations may be asso-
ciated with undifferentiated spondyloarthritis or suggest an alternative diagnosis, 
including a systemic disease such as inflammatory bowel disease and mechanical, 
developmental, and orthopedic disorders other than spondyloarthritis [41].
HLA-B27 is associated with enthesitis-related arthritis and has an increased 
incidence in all types of spondyloarthropathies. In juvenile ankylosing spondylitis, 
up to 90%, and in enthesitis-related arthritis, up to 50% can be positive [42].
13.2 Treatment
Treatment for spondyloarthritis aims to reduce symptoms, control inflammation, 
and prevent disability. The appropriate treatment depends on which manifestations 
are present, especially whether spinal involvement and whether spondyloarthritis is 
a manifestation of a systemic disease such as psoriatic arthritis, reactive arthritis, or 
inflammatory bowel disease. Traditional treatment with NSAIDs is recommended 
in all cases. In case of no response and active enthesitis, TNF inhibitor is preferable 
to methotrexate or sulfasalazine. In cases of TNF blocker contraindication, patients 
with mild enthesitis and patients with active peripheral polyarthritis, methotrexate 
or sulfasalazine can be used concomitantly. In cases of chronic active enthesitis, 
low-dose oral glucocorticoids can be used as bridge therapy in the short term (less 
than three months). In addition, this treatment can be used in cases of high disease 
activity, limited mobility, or significant symptoms [36, 42].
14. Conclusions
JIA is the most common cause of chronic arthritis in children. In approach to a 
child with chronic arthritis, the physician should be alert about the wide differential 
diagnoses and consider and rule in or rule out the probable causes according to the 
history and examination. A full history and physical examination will provide a 
good background for an appropriate approach. Unfortunately, there is not a specific 
diagnostic laboratory test for confirming the diagnosis. Some important causes such 
as infections, malignancies, metabolic disorders, endocrine diseases, connective 
tissue disorders, and immune deficiencies should be in the mind of the physician. 
Early diagnosis and aggressive treatment are the principles of the management 
to prevent significant disease complications. Long-term clinical, laboratory, and 
ophthalmologic follow-up are necessary.
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